Forward-Looking Statements

Forward-Looking Statements

This website contains various statements concerning our future expectations, plans and prospects, including, without limitation, statements related to our strategy, development and launch plans, and our treatment and business goals, that constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the potential regulatory path required for the AUGMENT and OvaPrime treatments outside of the United States; the science underlying our AUGMENT treatment and potential treatments, which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our AUGMENT treatment and potential treatments; our ability to obtain additional funding to support our business activities; our dependence on third parties for development (such as Intrexon), manufacture, marketing, sales and distribution of products; the successful development of our treatments on the timelines we expect; obtaining necessary regulatory approvals for our potential treatments; our ability to commercialize our AUGMENT treatment and potential treatments on the timelines we expect, if at all; competition from others developing treatments for similar uses; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recent 10-K and 10-Q and other reports on file with the Securities and Exchange Commission, which may be accessed under the “Investors” link in this website. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statement.